Abstract: A method of making a multi-grained fuel grain for a rocket is disclosed, the method comprising the steps of using at least one nozzle to extrude a first propellant in an additive manufacturing process, the first propellant comprising a multi-grained fuel grain, the multi-grained fuel grain forming the at least one void, the at least one void facilitating variation in internal ballistics, forming sensors, said sensors permitting continuous monitoring and continuous modification such that a user controls the ballistics profile of a rocket motor, forming an electrically-controlled second propellant in contact with and operatively coupled to the sensors; and wherein the additive manufacturing process uses at least at least one nozzle to extrude raw materials.

Abstract: A novel gRNA-ligand binding complex is provided. This complex may be used to bring Type V Cas proteins and additional effectors to DNA for base editing. The design of the systems allows for the production of efficient modular components that provide flexibility when editing DNA.

Abstract: A method of making a fuel grain for use in a rocket motor, the method comprising blending a first energetic nanoscale metallic compound and a second compound suitable to form a feedstock material for use in an additive manufacturing apparatus, the additive manufacturing apparatus operatively connected to a computing system, that provides additive manufacturing printing instructions to the additive manufacturing apparatus, permitting construction of an autonomously designed and optimized rocket fuel grain section; wherein the stochastic deposition simulation-assisted fuel grain geometries further comprise a plurality of agglutinated layers of solidified fuel grain compound, each layer of the plurality of layers comprising a plurality of blended and radially displaced beads of different radii, said radial displacement optionally optimized via competitive simulation programs, and wherein the system continuously mixes constituent materials in an inline/static mixer, with viscosity controlled via particle size var

Abstract: A computer program product comprising computer-readable code embodied in a non-transitory computer-readable storage medium which, when executed by one or more processors of a computing device, causes the computing device to perform a method comprising obtaining share portfolio information for one or more shareholders from a broker database, obtaining proxy voting requirements from at least one share issuer, receiving shareholder preference data from the one or more shareholders, generating proxy vote recommendations based on the share portfolio information, proxy voting requirements and the shareholder preference data, and providing the proxy vote recommendations to an interactive graphical interface of a shareholder access point using Application Programming Interface (API).

Abstract: A controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof is delivered to the subject. Also provided is a method of treating a disease or disorder (e.g., multiple sclerosis) by orally administering a controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof.

Abstract: A controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof is delivered to the subject. Also provided is a method of treating a disease or disorder (e.g., multiple sclerosis) by orally administering a controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof.

Abstract: A controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof is delivered to the subject. Also provided is a method of treating a disease or disorder (e.g., multiple sclerosis) by orally administering a controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof.

Abstract: A smart assistant scans or directs the scanning of a network and clients connected to the network to ensure that the clients will be properly backed up. When the smart assistant detects a change in the network, a client, or both, the smart assistant seeks the approval of a backup administrator to automatically update backup configuration information based on the detected change. If the backup administrator approves the approval request, the smart assistant automatically updates the backup configuration information. If the backup administrator denies the approval request, the smart assistant does not update the backup configuration information.

Abstract: A controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof is delivered to the subject. Also provided is a method of treating a disease or disorder (e.g., multiple sclerosis) by orally administering a controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof.

Abstract: A phototherapy treatment dispensing device provides therapeutic light emissions treatments. The device provides additional means for controlling a patient's exposure to those treatments through a controlled protocol timer. The controlled protocol timer can provide for incremental exposure increases; monitors patient compliance with a treatment regimen; and reminds the patient when a treatment will soon be overdue.

Abstract: A phototherapeutic device comprises a system for facilitating phototherapeutic treatment. The system comprises an input device configured to receive input from a user. The system further comprises a display device configured to communicate information to the user. The system further comprises a controller. The controller is configured to receive user identification data from the input device. The controller is further configured to retrieve treatment history based on the user identification data. The controller is further configured to retrieve a treatment protocol based on the user identification data. The controller is further configured to generate a suggested treatment based on the retrieved treatment history and the retrieved treatment protocol. The controller is further configured to communicate the suggested treatment to the display device.

Abstract: A phototherapy treatment dispensing device provides therapeutic light emissions treatments. The device provides additional means for controlling a patient's exposure to those treatments through a controlled protocol timer. The controlled protocol timer can provide for incremental exposure increases; monitors patient compliance with a treatment regimen; and reminds the patient when a treatment will soon be overdue.

Abstract: A system and method for validation, review, approval, editing, developing, publishing, and/or ongoing maintenance of a digital document, the system and method having the functionality to work alone or can be used in conjunction with other software applications and workflows in order to facilitate the direct review of documents.

Abstract: Various embodiments of the present disclosure provide a combination strapping package and dispenser that includes a first strapping coil holding compartment and a second strapping coil holding compartment configured to be nested together and to define a coil receiving or holding area. The combination strapping package and dispenser is configured to hold a strapping coil during shipment from the manufacturer or distributor to the end user and additionally during the use of the strapping by the end user such that the end user does not need to remove the strapping coil from the combination strapping package and dispenser. In certain embodiments, the combination strapping package and dispenser of the present disclosure is configured for mid-range amounts of coil which are easier to transport and use, is compostable, and requires less cost to ship.

Abstract: An apparatus for delivering at least one therapeutic agent to a dental tissue of a subject includes at least one electrode, a medicament layer including at least one therapeutic agent, an electrical signal source, and logic configured to control the electrical signal source. At least one electrode has oppositely disposed, dental mouthpiece-shaped first and second major surfaces. The first major surface is curved such that the first major surface substantially conforms to the contour of the dental tissue when placed in contact with the dental tissue. The medicament layer is disposed on at least a portion of the second major surface. The electrical signal source provides a signal having certain characteristics and is electrically connected to at least one electrode. The certain characteristics comprise at least one orienting frequency and at least one motivating frequency sufficient to motivate at least one therapeutic agent into the dental tissue.

Abstract: A phototherapy treatment dispensing device provides therapeutic light emissions treatments. The device provides additional means for controlling a patient's exposure to those treatments through a controlled protocol timer. The controlled protocol timer can provide for incremental exposure increases; monitors patient compliance with a treatment regimen; and reminds the patient when a treatment will soon be overdue.

Abstract: The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferrably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.

Abstract: The present invention is concerned with novel compounds useful in the treatment of hyperproliferative diseases and mammalian cancers, especially human cancers. The invention also pertains to methods of modulating kinase activities, pharmaceutical compositions, and methods of treating individuals, incorporating or using the compounds. The preferred compounds are active small molecules set forth in formulae Ia-Iww.

Abstract: A software system automatically and dynamically generates a fully functional user interface (UI) based upon, and connected directly to, an underlying data model (as instantiated within a relational database management system (RDBMS)). The UI derives from an automated interrogation of the RDBMS, and comprises all mode displays (e.g., browse, search, edit, add) for all tables, and a full complement of mechanisms—integrated directly into the mode displays—for representing, navigating, and managing relationships across tables, regardless of the complexity of the underlying RDBMS schema. It utilizes a hierarchical “context stack” for suspending the working state of a particular table while “drilling down” to work with related-table information and return relevant changes to the base table.